Daily Ards Research Analysis
Analyzed 12 papers and selected 3 impactful papers.
Summary
An emulated target trial in severe COVID-19 respiratory failure links late intubation to markedly worse 60-day survival, underscoring risks of prolonged non-invasive support in progressive failure. Bedside bronchoscopic confocal laser endomicroscopy (CLE) proved feasible and safe in ventilated ARDS patients, revealing microstructural changes beyond CT. A biomarker study found markedly elevated heparin-binding protein in critical COVID-19 but no prognostic utility for HBP or ET-1 at ICU admission.
Research Themes
- Timing of intubation and non-invasive respiratory support strategies
- Bedside microscopic imaging to phenotype ARDS beyond CT
- Limits of single-endotheliopathy biomarkers for prognostication
Selected Articles
1. Delayed intubation and 60-day mortality in severe COVID-19-associated acute respiratory failure in an emulated target trial using the OUTCOMEREA network.
In an emulated target trial of 234 ICU patients at risk of intubation between days 7–12, late intubation was associated with higher 60-day mortality (adjusted HR 2.89; 95% CI 1.50–3.92). Patients who underwent late intubation had a 78.5% 60-day mortality and a 17.8-day shorter restricted mean survival time versus continued NIRS.
Impact: Provides robust causal-inference evidence that prolonged NIRS with late intubation is linked to excess mortality, directly informing airway management strategies in severe COVID-19 respiratory failure.
Clinical Implications: In patients with progressive failure despite NIRS, earlier identification and timely intubation should be prioritized over prolonged non-invasive support. Protocols should incorporate dynamic reassessment triggers to avoid harmful delays.
Key Findings
- Late intubation between ICU days 7–12 was associated with increased 60-day mortality (adjusted HR 2.89; 95% CI 1.50–3.92).
- Among patients intubated after day 6, the 60-day mortality was 78.5%.
- Restricted mean survival time was 17.8 days shorter in the late intubation group.
Methodological Strengths
- Emulated target trial design with weighted Cox models to mitigate time-dependent confounding
- Multicentre cohort from a prospective ICU database (OUTCOMEREA)
Limitations
- Observational design with potential residual confounding and selection of patients still in ICU by day 7
- Generalizability limited to COVID-19-era practices; no randomization of intubation timing
Future Directions: Prospective trials or adaptive protocols testing early intubation triggers versus prolonged NIRS in high-risk phenotypes, leveraging continuous physiological monitoring.
The benefits of non-invasive respiratory support strategies (NIRS), such as high-flow nasal oxygen therapy, in delaying intubation remain uncertain. We used an emulated target trial approach to evaluate outcomes associated with late intubation in patients with severe acute respiratory failure due to COVID-19. We conducted a retrospective multicentre cohort study using the French prospective OUTCOMEREA database. Adult patients admitted to intensive care units (ICUs) for severe SARS-CoV-2 pneumonia with an ICU length of stay of at least seven days were included in the study. Descriptive analyses were used to compare patients who were intubated after day 6 with those who remained under NIRS. In the emulated target trial, patients who were eligible between ICU days 7 and 12 were assigned to undergo late intubation or to remain under NIRS. Weighted Cox proportional hazards models were used. The primary outcome was 60-day mortality.
2. Confocal laser endomicroscopy in patients with acute respiratory failure.
Among 33 ventilated ICU patients (41 procedures; 150 videos), bedside bronchoscopic CLE achieved 100% procedural feasibility with no CLE-related adverse events. CLE identified alveolar filling and architectural patterns and detected abnormalities in most CT-normal segments, revealing early microstructural remodeling; ex vivo CLE findings matched histopathology in an autopsy case.
Impact: Introduces a feasible, safe bedside imaging modality with near-histologic resolution that reveals alveolar microstructure beyond CT, enabling earlier detection of remodeling in ARDS.
Clinical Implications: CLE could complement CT to phenotype ARDS at the bedside, inform ventilator strategies, and identify candidates for antifibrotic or precision therapies earlier in the disease course.
Key Findings
- Procedural feasibility was 100% across 41 CLE procedures with no CLE-related adverse events.
- CLE detected abnormalities in 6/7 CT-normal segments and architectural changes in 60/78 ground-glass segments.
- Alveolar patterns included air (63%), fluid (12%), and cells (25%); architecture showed increased elastin with preserved (53%) or distorted (19%) patterns; ex vivo CLE aligned with histopathology.
Methodological Strengths
- Prospective bedside imaging integrated with clinically indicated BAL and predefined feasibility/safety endpoints
- Qualitative CT comparison and ex vivo histopathologic concordance supporting biological validity
Limitations
- Single-center pilot with small sample size and primarily qualitative analyses
- Lack of standardized quantitative CLE-CT correlation and limited outcome linkage
Future Directions: Standardize CLE acquisition/interpretation, correlate with longitudinal outcomes and biomarkers, and test whether CLE-guided strategies improve ARDS management.
BACKGROUND: Survivors of the early exudative phase of acute respiratory distress syndrome (ARDS) may develop a fibroproliferative repair response and persistent microstructural remodeling associated with adverse outcomes. Conventional imaging, including chest computed tomography (CT), has limited biological specificity for early microscopic remodeling. Confocal laser endomicroscopy (CLE) enables real-time bronchoscopic imaging of the alveolar compartment with near-histologic resolution. We evaluated the feasibility and safety of bedside bronchoscopic CLE in invasively ventilated ICU patients with acute respiratory failure and explored whether in vivo CLE provides microscopic alveolar information complementary to chest CT. METHODS: In this single-center observational pilot study, mechanically ventilated adult ICU patients with a clinical indication for bronchoalveolar lavage (BAL) underwent additional bedside bronchoscopic CLE. Primary endpoints were feasibility (≥ 1 interpretable alveolar video with visible septal architecture per procedure) and safety (CLE-related adverse events within 24 h). Secondary exploratory endpoints were dominant in vivo CLE patterns of alveolar filling (air, fluid, cells) and architecture (thin elastin fibers with hexagonal architecture; increased elastin with preserved architecture; increased elastin with distortion) and qualitative comparison with CT abnormalities in the imaged segments.
3. Heparin-binding protein and Endothelin-1 in critical COVID-19.
HBP levels were markedly elevated in critical COVID-19 compared with post-trauma ICU controls (median 150 vs 13.3 ng/ml; p<0.0001), yet neither HBP nor ET-1 at ICU admission predicted 60-day mortality or IMV. ET-1 was higher in those needing IMV in unadjusted analyses, but the association disappeared after adjustment; HBP and ET-1 did not correlate.
Impact: Delivers a rigorously analyzed negative result that challenges reliance on single inflammatory/endothelial biomarkers for early risk stratification in critical COVID-19/ARDS.
Clinical Implications: Routine measurement of HBP or ET-1 at ICU admission should not guide prognostication or ventilation decisions in critical COVID-19; multimodal models or dynamic biomarker trajectories may be needed.
Key Findings
- HBP was markedly elevated in critical COVID-19 versus post-trauma ICU patients (median 150 vs 13.3 ng/ml; p<0.0001).
- HBP levels at admission did not associate with 60-day mortality or need for invasive mechanical ventilation.
- ET-1 levels were not different between cohorts and did not independently predict mortality or IMV after adjustment; no correlation between HBP and ET-1.
Methodological Strengths
- Prospective sampling at ICU admission with standardized biomarker assays
- Adjustment for key covariates in regression and inclusion of a comparator ICU cohort
Limitations
- Modest sample size and single time-point measurements may miss informative trajectories
- Single-year cohort (2020) and evolving COVID-19 care limit generalizability
Future Directions: Evaluate longitudinal biomarker trajectories and integrate endothelial and inflammatory panels into multimodal prognostic models validated across ARDS etiologies.
BACKGROUND: Heparin-binding protein (HBP) is an inflammatory protein released by activated polymorphonuclear white cells. It has been suggested as a predictor of sepsis progression and organ dysfunction and plays a role in the pathophysiology of endothelial dysfunction. Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor with pro-inflammatory effects, and high levels are found in patients with sepsis and acute respiratory distress syndrome. We investigated HBP and ET-1 plasma levels in critical COVID-19 disease with the aim of evaluating whether they were associated with 60-day mortality or the need for invasive mechanical ventilation (IMV). These levels were compared with those of a cohort of post-trauma intensive care unit (ICU) patients. METHODS: We included 96 patients with critical COVID-19 disease in 2020 and ten post-trauma ICU patients. Blood samples were collected at ICU admission, and plasma levels of HBP and ET-1 were measured. Clinical and laboratory data were collected until ICU discharge or death.